Pharmaceutical companies are trying to navigate emerging global guidance and regulation of AI and data, something that can be difficult given the different approaches taken in different jurisdictions, according to AstraZeneca’s director of data and AI policy, Margi Sheth.
“It’s tricky to interpret all of this [regulation] and navigate spaces that are disjointed or not congruent, so we really advocate for [legislators] to continue engaging industry on the practical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?